September 20, 2019 10:38 AM EDT
Deals

Boehringer In­gel­heim en­lists an­oth­er vir­tu­al biotech part­ner for its for­ay in­to reti­nal dis­eases

Amber Tong

Boehringer In­gel­heim is bet­ting on reti­nal ther­a­pies in its lat­est deal and, in do­ing so, shin­ing the spot­light on a lit­tle-known biotech that has some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times